Somanetics Reports 28 Percent Increase in Sales and 27 Percent Increase in Net Income for the First Quarter of Fiscal 2009
Posted on: Wednesday, 18 March 2009, 06:30 CDT
First Quarter Highlights
-- Net revenues of
-- Income before income taxes of
-- Net income of
U.S. net revenues increased 17 percent to
First quarter income before income taxes was
Gross margin was 86 percent in the first quarter, compared with 88 percent in the first quarter of 2008. As of
"We delivered solid financial results in the first quarter, particularly given the current economic environment," said
"We anticipate that fiscal 2009 will be a year of continued growth for Somanetics and its technology, and we also view it as a year of substantial investment," Barrett continued. "During the first quarter, we invested in sales, marketing and medical education to develop the neonatal ICU market. We are supporting our marketing initiatives with clinical research related to the use of the INVOS System in the neonatal ICU, and expect research to be presented at conferences later in 2009. In addition, we are continuing to make investments within R&D to capitalize on a number of opportunities to expand the applications for our technology."
Sales and Marketing Activities
During the second quarter, Somanetics will participate in approximately 20 medical conferences, including the 2009 annual meeting of the American Association for Thoracic Surgery and various regional and state cardiothoracic, perfusion, anesthesia, pediatric cardiac and neonatology association meetings.
Research and Development
Somanetics is continuing to develop a number of research and development projects. In late 2008, Somanetics acquired substantially all of the assets of ICU Data Systems, including its patented data integration technology. In the second quarter of fiscal 2009, Somanetics expects to launch a stand-alone device that integrates data from a broad array of hospital bedside devices, such as physiological monitors, ventilators and infusion devices, into a single bedside display for comparison, data management and storage.
Business Outlook
Based on its first quarter results, Somanetics is reaffirming its financial guidance for fiscal year 2009. Somanetics is currently forecasting:
- Fiscal 2009 net revenues of approximately
$54.6 million , a 15 percent increase over 2008. - Gross margin of approximately 86 percent and operating margin of approximately 20 percent.
- Fiscal 2009 income before income taxes of approximately
$12 million .
Current estimates are based on market and economic conditions, including the assumption that the current economic downturn continues throughout 2009, and Somanetics' current plans to invest in several areas of its business. Such investments include clinical research, medical education, research and development projects focused on the pediatric and neonatal ICU markets, the development of the ICU Data Systems technology and the addition of several international sales employees. Somanetics undertakes no obligation to update its estimates.
Somanetics to Host Conference Call
Somanetics will web cast its 2009 first quarter conference call at
About Somanetics
Somanetics Corporation (Nasdaq: SMTS) develops, manufactures and markets the INVOS(R) Cerebral/Somatic Oximeter, a non-invasive patient monitoring system that continuously measures changes in the blood oxygen levels in the brain and elsewhere in the body in patients with or at risk for restricted blood flow. Surgeons, anesthesiologists and other medical professionals can use the information provided by the INVOS System, in conjunction with other available information, to identify oxygen imbalances in tissues beneath the sensor and take necessary corrective action, potentially improving patient outcomes and reducing the costs of care. The INVOS System has an 11-year market track record supported by more than 600 clinical references, and is used at more than 700 U.S. hospitals. Somanetics also is developing a technology that integrates data from bedside devices into a single display for comparison, data management and data storage. Somanetics supports its customers through a direct U.S. sales force and clinical education team. Covidien markets INVOS System products in
Safe-Harbor Statement
Except for historical information contained herein, the matters discussed in this news release, including financial guidance for fiscal year 2009, are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Actual results may differ significantly from results discussed in the forward-looking statements and may be affected by, among other things, economic conditions in general and in the healthcare market, including the recent global economic crisis, the demand for and market acceptance of our products in existing market segments and in new market segments we plan to pursue, our current dependence on the Cerebral Oximeter and disposable sensors, our dependence on distributors for a substantial portion of our sales, our dependence on single-source suppliers, potential competition, the effective management of our growth, our ability to attract and retain key personnel, the potential for products liability claims, government regulation of our business, the challenges associated with developing new products and obtaining and maintaining regulatory approvals if necessary, research and development activities, the lengthy sales cycle for our products, sales employee turnover, changes in our actual or estimated future income, changes in accounting rules, enforceability and the costs of enforcement of our patents, potential infringements of others' patents, the effect of acquisitions and the other factors set forth from time to time in Somanetics' Securities and Exchange Commission filings, including Somanetics' 2008 Annual Report on Form 10-K filed on
(Tables to follow)
SOMANETICS CORPORATION BALANCE SHEETS February 28, November 30, 2009 2008 ---- ---- ASSETS (Unaudited) (Audited) CURRENT ASSETS: Cash and cash equivalents $23,946,800 $37,166,141 Marketable securities 20,015,485 19,992,545 Accounts receivable 7,187,642 7,862,103 Inventory 3,200,353 2,960,422 Prepaid expenses 529,492 597,460 Accrued interest receivable 92,636 16,667 Deferred tax asset - current 164,615 164,615 ------- ------- Total current assets 55,137,023 68,759,953 ---------- ---------- PROPERTY AND EQUIPMENT (at cost): Demonstration and no capital cost sales equipment at customers 4,037,213 3,919,296 Machinery and equipment 1,737,499 1,638,597 Furniture and fixtures 504,485 504,485 Leasehold improvements 197,450 197,450 ------- ------- Total 6,476,647 6,259,828 Less accumulated depreciation and amortization (3,631,745) (3,418,697) ---------- ----------- Net property and equipment 2,844,902 2,841,131 --------- --------- OTHER ASSETS: Long-term investments 27,634,325 12,837,710 Deferred tax asset - non-current 1,587,977 1,587,977 Intangible assets, net 243,239 246,318 Goodwill 1,679,713 1,679,713 Other 15,000 15,000 ------ ------ Total other assets 31,160,254 16,366,718 ---------- ---------- TOTAL ASSETS $89,142,179 $87,967,802 =========== =========== LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $1,070,770 $1,271,058 Accrued liabilities 819,872 1,848,672 ------- --------- Total current liabilities 1,890,642 3,119,730 --------- --------- COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred shares; authorized, 1,000,000 shares of $.01 par value; no shares issued or outstanding Common shares; authorized, 20,000,000 shares of $.01 par value; issued and outstanding, 12,042,662 shares at February 28, 2009, and 12,034,074 shares at November 30, 2008 120,427 120,341 Additional paid-in capital 92,431,505 91,330,305 Accumulated deficit (5,300,395) (6,602,574) ---------- ---------- Total shareholders' equity 87,251,537 84,848,072 ---------- ---------- TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $89,142,179 $87,967,802 =========== =========== STATEMENTS OF OPERATIONS (Unaudited) For the Three-Month Periods Ended ------------- February 28, February 29, 2009 2008 ---- ---- NET REVENUES $11,155,354 $8,693,274 COST OF SALES 1,580,481 1,016,824 --------- --------- Gross Margin 9,574,873 7,676,450 --------- --------- OPERATING EXPENSES: Research, development and engineering 423,161 330,436 Selling, general and administrative 7,314,699 6,498,148 --------- --------- Total operating expenses 7,737,860 6,828,584 --------- --------- OPERATING INCOME 1,837,013 847,866 --------- ------- OTHER INCOME: Interest income 271,386 934,418 ------- ------- Total other income 271,386 934,418 ------- ------- INCOME BEFORE INCOME TAXES 2,108,399 1,782,284 --------- --------- INCOME TAX EXPENSE (806,220) (753,855) --------- --------- NET INCOME $1,302,179 $1,028,429 ========== ========== NET INCOME PER COMMON SHARE - BASIC $ .11 $ .08 ========== ========== NET INCOME PER COMMON SHARE - DILUTED $ .10 $ .07 ========== ========== WEIGHTED AVERAGE SHARES OUTSTANDING - BASIC 12,038,368 13,450,691 ========== ========== WEIGHTED AVERAGE SHARES OUTSTANDING - DILUTED 12,898,920 14,759,732 ========== ==========SOURCE Somanetics Corporation
Source: PR Newswire
Related Articles
- CMS Energy Announces Second Quarter Net Income of $74 Million, or $0.32 Per Share, and Affirms Adjusted Earnings Guidance
- Thor Announces Sales, Net Income, E.P.S. for Quarter, Nine Months Increases Market Share in Both RV and Bus
- Shiner International Announces First Quarter 2009 Results, Recent Increase in Sales; Annual Meeting of Shareholders to Be Held June 5th
- CMS Energy Reports First Quarter Net Income of $69 Million, or $0.30 Per Share, and Affirms Adjusted Earnings Guidance
- RF Micro Devices Announces March 2009 Quarterly Results
- Waste Services Announces First Quarter 2009 Results and Provides Earnings Per Share Guidance
- Interline Brands, Inc. Announces Fourth Quarter and Fiscal 2008 Sales and Earnings Results
- CMS Energy Announces Third Quarter Net Income of $79 Million, or $0.34 Per Share, and Affirms Earnings Guidance
- CEDC Previews 3rd Quarter Performance; Reconfirms 2008 Sales and Fully Diluted EPS Guidance
- CMS Energy Announces Second Quarter Net Income of $46 Million, or $0.19 Per Share, and Affirms Earnings Guidance
 |
 |
User Comments (0)
RSS Feeds